1.80 USD
↗ 0.09 (5.26%)AT CLOSE (11:59 AM EDT)
Annovis Bio, Inc.
ANVSNYSE • USD
1.80
↘ 0.00 (0.06%)
POST MARKET (AS OF 08:15 PM EDT)
Post Market
AS OF 08:15 PM EDT
1.80
↘ 0.00 (0.06%)
Market: CLOSED
Annovis Bio, Inc. (ANVS) trades at $1.80 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, ANVS is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Jul 15, 2026.
Open?$1.72
High?$1.83
Low?$1.71
Prev. Close?$1.71
Volume?465.3K
Avg. Volume?1.0M
VWAP?$1.78
Rel. Volume?0.45x
Bid / Ask
Bid?$1.71 × 2.9K
Ask?$1.81 × 500
Spread?$0.10
Midpoint?$1.76
Valuation & Ratios
Market Cap?76.6M
Shares Out?34.6M
Float?30.3M
Float %?87.3%
P/E Ratio?N/A
P/B Ratio?24.50
EPS?-$0.96
Dividend?0.00%
Ex-Dividend?N/A
RelatedALXO
News
Profile
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Employees
7
Market Cap
72.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-01-29
Address
101 LINDENWOOD DRIVE, SUITE 225
MALVERN, PA 19355
Phone: 484-875-3192
MALVERN, PA 19355
Phone: 484-875-3192
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?23
Short Sent.?31
Piotroski F-Score?0/9Weak
Altman Z-Score?-20.28Distress
Confidence?58%Low
Short InterestHigh
Short % of Float?16.08%High
Short Interest?4.9M
Days to Cover?5.4
Free Float30.3M
Avg Daily Volume908.3K
Settlement Date2026-06-30
Financial Health
Current Ratio?1.27Adequate
Quick Ratio?1.27Adequate
Cash Ratio?1.11Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?24.50HIGH▾
Peers50
S&P3
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.5CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-1,309.1%WEAK▾
S&P3
ROA?-251.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$62.4M
Fundamentals ratios updated end of day